Table 2.
Chemotherapy regimens before gefitinib treatment, alcohol history, and hepatitis virus
| Liver damage induced by gefitinib | 1st regimen before gefitinib therapy | 2nd regimen before gefitinib therapy | Alcohol consumption | Hepatitis virus |
|---|---|---|---|---|
| Occurred | CDDP + DOCa | – | Nondrinker | Negative |
| CDDP + PEMb | DOCa | Nondrinker | Negative | |
| CDDP + PEMa | GEM + VNRa | 30.8 g/day | Negative | |
| CBDCA + PEMa | – | Nondrinker | Negative | |
| CBDCA + DOCb | – | Nondrinker | HCV | |
| UFTb | – | Nondrinker | Negative | |
| UFTb | – | Nondrinker | Negative | |
| Did not occur | CDDP + DOCa | PEMa | Social drinker | Negative |
| CDDP + PEM + BEVa | – | Nondrinker | Negative | |
| GEM + VNRa | – | Nondrinker | Negative |
Notes:
a
Chemotherapy for postoperative recurrence or inoperative cases;
b
postoperative adjuvant chemotherapy.
Abbreviations: CDDP, cisplatin; DOC, docetaxel; PEM, pemetrexed sodium; GEM, gemcitabine; VNR, vinorelbine; CBDCA, carboplatin; UFT, tegafur-uracil; BEV, bevacizumab; HCV, hepatitis C virus.